Stock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition

Stock Track

01/07

Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The potential deal would significantly boost Lilly's portfolio with Ventyx's pipeline of drugs targeting inflammatory bowel diseases like Crohn's disease and ulcerative colitis, as well as treatments for Parkinson's disease and cardiovascular conditions linked to obesity.

The Wall Street Journal first reported the acquisition talks, citing people familiar with the matter. Ventyx's experimental drugs, particularly those in mid-stage clinical trials, have attracted significant interest from large pharmaceutical companies, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1118501726"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118501726\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118501726?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118501726","market":"hk","top_or_hot":-1,"title":"Stock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition","media":"Stock Track","content":"<p>Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The potential deal would significantly boost Lilly's portfolio with Ventyx's pipeline of drugs targeting inflammatory bowel diseases like Crohn's disease and ulcerative colitis, as well as treatments for Parkinson's disease and cardiovascular conditions linked to obesity.</p><p>The Wall Street Journal first reported the acquisition talks, citing people familiar with the matter. Ventyx's experimental drugs, particularly those in mid-stage clinical trials, have attracted significant interest from large pharmaceutical companies, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-07 17:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The potential deal would significantly boost Lilly's portfolio with Ventyx's pipeline of drugs targeting inflammatory bowel diseases like Crohn's disease and ulcerative colitis, as well as treatments for Parkinson's disease and cardiovascular conditions linked to obesity.</p><p>The Wall Street Journal first reported the acquisition talks, citing people familiar with the matter. Ventyx's experimental drugs, particularly those in mid-stage clinical trials, have attracted significant interest from large pharmaceutical companies, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTYX","symbol_name":"Ventyx Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1118501726","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118501726","pubTimestamp":1767777178,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTYX":"Ventyx Biosciences, Inc."},"translate_title":"个股追踪|Ventyx Biosciences盘前大涨69.25%礼来有意10亿美元收购","themeId":"d9d938951d4e1d58a135a999ef2d5d12","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTYX":1},"content_text":"Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The potential deal would significantly boost Lilly's portfolio with Ventyx's pipeline of drugs targeting inflammatory bowel diseases like Crohn's disease and ulcerative colitis, as well as treatments for Parkinson's disease and cardiovascular conditions linked to obesity.The Wall Street Journal first reported the acquisition talks, citing people familiar with the matter. Ventyx's experimental drugs, particularly those in mid-stage clinical trials, have attracted significant interest from large pharmaceutical companies, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}